Lanifibranor, a pan-PPAR agonist, was tested in a phase 2b trial with 247 patients with highly active MASH, showing significant liver histology improvements without worsening fibrosis [142,143]; a phase 3 trial (NCT04849728) with 1000 participants is ongoing to confirm these findings [144]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.